Article Listing - Generics
Generic drugs and APIs push Indian pharma sector growth
21 December 2009
The pharmaceutical industry in Indian achieved a significant growth of 13.44% during the 2004-09 period, due to strong internal demand and continuous focus in the global generics market and a significant share in the exports of Active Pharmaceuticals Ingredients (APIs), according to a new report added to the offering of Research and Markets.
UNITAID HIV patent pool could save over $1 billion a year, put pressure on AIDS drugmakers
17 December 2009
In a move that could put pressure on HIV/AIDS drugmakers to ease control of their patented products, yesterday the French-backed health fund UNITAID said that its executive board has made a landmark decision to establish a Patent Pool for AIDS medicines. The organization’s founder members include the UK, Chile, Brazil, Norway and France.
Hospira to buy Orchid's generic injectable business for $400 million
16 December 2009
The USA’s Hospira has entered into a deal to acquire the generic injectable finished-dosage form pharmaceuticals business of India’s Orchid Chemicals & Pharmaceuticals, which is among the top-five generic beta-lactam antibiotics manufacturers globally, for around $400 million.
Turkey’s new drug pricing decree will shrink Pharma industry by 25%, say drugmakers
15 December 2009
December 4, the effective date of the new drug pricing decree in Turkey, marks the beginning of a period of decline in the Turkish pharmaceutical industry where, initially, a contraction of about 25% is expected. In preparation for difficult times, drugmakers are reconsidering their investment and employment plans, beginning layoffs, with projections of a higher number of university graduates losing jobs in 2010, according to the Turkish research-based drug industry group the AiFD.
The Polish pharmaceutical market: how major drugmakers view it
15 December 2009
The Polish pharmaceutical market has grown dynamically in the past five years, showing great resilience to the impact of adverse trends prevailing in the market. As demonstrated by the results of the most recent study conducted by the advisory company KPMG and the Poland-based research company PMR in June 2009, the current economic situation linked to the global economic crisis has not affected the good performance of the pharmaceutical industry; either, it has not had an adverse effect on the optimistic mood prevailing among pharmaceutical companies in Poland.
UK regulatory agency clears prostate drug Flomax for OTC use; generic competition due next year in USA
14 December 2009
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has recently approved of the first over-the-counter (OTC) medicine to treat the symptoms of benign prostatic hyperplasia (BPH) in men, to be available through pharmacies without a prescription.
Generic usage rates in USA surpass all-time industry highs, according to new study
11 December 2009
Prescription Solutions, a US pharmacy benefits management (PBM) organization, says it has achieved an industry-leading overall generic prescription drug penetration rate of 68.8% percent year-to-date for 2009.
Spanish consumers not benefiting from generics
11 December 2009
According to a report in the Spanish newspaper The Vanguard, the savings from competition that allows generic drug manufacturers to sell their products more cheaply than originator drugs does not end up in the pockets of the consumers nor of the public health system, with price discounts, to a large extent, benefitting pharmacies, according to the first study made by the Catalan Autoritat of Competencia (ACC).
US Senate debating Dorgan’s importation of prescription drugs bill; strong opposition from several quarters
10 December 2009
Under bipartisan legislation that US Senator Byron Dorgan (Democrat, North Dakota) is pushing to include in the health reform bill, it is estimated that the federal government could save $19.4 billion over the next ten years. The Senate is expected to vote this week on Dorgan’s amendment.
Europe needs new legislation on counterfeiting, says EPHA
10 December 2009
Contributing to the debate in the European Parliament and Council on the Falsified Medicines Directive from the so-called Pharmaceutical package, the European Public Health Alliance (EPHA) said that patients safety and the access to high- quality medicinal products represent key issues in pharmaceutical policy, but further legislation is required. In this context, the EPHA welcomes the Commission’s legislative initiative aimed at combating counterfeit medicine, and more particularly for the following reasons:
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
